Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Por:
Cejalvo J, De Duenas E, Galvan P, Garcia-Recio S, Gasion O, Pare L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Munoz M, Nuciforow P, Vidal M, Perez R, Lopez-Muniz J, Caballero R, Peg V, Carrasco E, Rojo F, Perou C, Cortes J, Adamo V, Albanell J, Gomis R, Lluch A, Prat A
Publicada:
1 may 2017
Resumen:
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and chi(2) tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus primary disease. Metastatic tumors were enriched for proliferation-related and migration-related genes and diminished for luminal-related genes. Expression of proliferation-related genes were better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at predicting OSmet in primary disease compared with metastatic tissue. We observed correlations between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment. (C) 2017 AACR.
Filiaciones:
Cejalvo J:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Inst Res Biomed IRB Barcelona, Oncol Program, Barcelona, Spain
De Duenas E:
Hosp Prov Castellon, Castellon de La Plana, Spain
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Galvan P:
Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain
Garcia-Recio S:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Gasion O:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain
Pare L:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Antolin S:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Complejo Hosp Univ A Coruna, La Coruna, Spain
Martinello R:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Blancas I:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Complejo Hosp Granada, Hosp Clin San Cecilio, Granada, Spain
Adamo B:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Guerrero-Zotano A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Inst Valenciano Oncol, Valencia, Spain
Munoz M:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Nuciforow P:
Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain
Vidal M:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Perez R:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Univ Quiron Madrid, Madrid, Spain
Lopez-Muniz J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Virgen de la Salud, Toledo, Spain
Caballero R:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Peg V:
Hosp Valle De Hebron, Pathol Dept, Barcelona, Spain
Carrasco E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Rojo F:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Fdn Jimenez Diaz, Madrid, Spain
CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain
Perou C:
Univ N Carolina, Chapel Hill, NC USA
Cortes J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ramon & Cajal Univ Hosp, Madrid, Spain
Adamo V:
Univ Messina, Messina, Italy
Albanell J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Mar, Barcelona, Spain
CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain
Gomis R:
Inst Res Biomed IRB Barcelona, Oncol Program, Barcelona, Spain
ICREA, Barcelona, Spain
Lluch A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Univ Valencia, Biomed Res Inst INCLIVA, Dept Hematol & Med Oncol, Valencia, Spain
CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain
Prat A:
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain
|